vimarsana.com


Dive Brief:
Amgen on Monday said it has submitted for Food and Drug Administration approval its asthma drug hopeful tezepelumab, advancing a medicine that's crucially important to its plans for growing beyond the aging blockbusters that have sustained its business for years. 
Tezepelumab, which Amgen has developed with partner AstraZeneca for nearly a decade, is a biologic drug that works to reduce airway inflammation in a new way. By blocking a protein known as TSLP, tezepelumab is thought to prevent the release of other, pro-inflammatory proteins, thereby reducing asthma attacks. 
Results from a study called NAVIGATOR, released in November, bore this hypothesis out, showing treatment with the drug reduced attacks in patients with severe asthma. But data from a much smaller clinical trial just one month later raised some questions about how competitive tezepelumab might be. 

Related Keywords

United States ,American ,Rd David Reese ,Robert Bradway ,Amgen ,Astrazeneca ,Drug Administration ,American Thoracic Society ,Dive Brief ,Five Prime Therapeutics ,ஒன்றுபட்டது மாநிலங்களில் ,அமெரிக்கன் ,ர்ட் டேவிட் ரீஸ் ,ராபர்ட் பிராட்வே ,மகேன் ,அமெரிக்கன் தொராசி சமூகம் ,டைவ் சுருக்கமான ,ஐந்து ப்ரைம் சிகிச்சை ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.